{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:35:09Z","timestamp":1791909309237,"version":"4.3.4"},"reference-count":162,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/crd.0b013e318248a3e1","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T06:09:59Z","timestamp":1328335799000},"page":"197-207","source":"Crossref","is-referenced-by-count":40,"title":["Growth Hormone and the Cardiovascular System"],"prefix":"10.1097","volume":"20","author":[{"given":"Christopher R.","family":"Palmeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderpreet Kaur","family":"Dardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivas","family":"Balasubramaniyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica D.","family":"Schwarcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"issue":"suppl 5","key":"R2-7-20210203","first-page":"166","article-title":"Excess mortality in acromegaly.","volume":"68","author":"Holdaway","year":"2007","journal-title":"Horm Res"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2265.1994.tb03789.x","article-title":"Determinants of clinical outcome and survival in acromegaly.","volume":"41","author":"Rajasoorya","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1074\/jbc.271.10.5947","article-title":"Participation of JAK and STAT proteins in growth hormone-induced signaling.","volume":"271","author":"Han","year":"1996","journal-title":"J Biol Chem"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/excr.1994.1224","article-title":"Acute myocardial infarction leads to upregulation of the IGF-1 autocrine system, DNA replication, and nuclear mitotic division in the remaining viable cardiac myocytes.","volume":"213","author":"Reiss","year":"1994","journal-title":"Exp Cell Res"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-81-1-11","article-title":"Acromegaly and cardiovascular disorders. A prospective study.","volume":"81","author":"McGuffin","year":"1974","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1530\/eje.0.151s093","article-title":"The heart: an end-organ of GH action.","volume":"151","author":"Colao","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"suppl 1","key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1530\/EJE-09-0291","article-title":"Cardiovascular risk factors in hypopituitary GH-deficient adults.","volume":"161","author":"Verhelst","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.","volume":"30","author":"Moller","year":"2009","journal-title":"Endocr Rev"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0008-6363(95)00163-8","article-title":"Insulin-like growth factor I and its binding proteins in the cardiovascular system.","volume":"30","author":"Delafontaine","year":"1995","journal-title":"Cardiovasc Res"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11102-008-0138-y","article-title":"Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886).","volume":"12","author":"de Herder","year":"2009","journal-title":"Pituitary"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2003-0009","article-title":"Cardiovascular function in acromegaly.","volume":"24","author":"Clayton","year":"2003","journal-title":"Endocr Rev"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1126\/science.3563497","article-title":"Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus.","volume":"236","author":"Han","year":"1987","journal-title":"Science"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1161\/01.CIR.87.5.1715","article-title":"Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes.","volume":"87","author":"Ito","year":"1993","journal-title":"Circulation"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"22892","DOI":"10.1074\/jbc.M011647200","article-title":"Demonstration of direct effects of growth hormone on neonatal cardiomyocytes.","volume":"276","author":"Lu","year":"2001","journal-title":"J Biol Chem"},{"key":"R20-7-20210203","first-page":"357","article-title":"Cardiac architectural changes with hypertrophy induced by excess growth hormone in rats.","volume":"59","author":"Lei","year":"1988","journal-title":"Lab Invest"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0024-3205(00)00759-1","article-title":"Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes.","volume":"67","author":"Chen","year":"2000","journal-title":"Life Sci"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/01.CIR.99.11.1426","article-title":"Cell death in acromegalic cardiomyopathy.","volume":"99","author":"Frustaci","year":"1999","journal-title":"Circulation"},{"issue":"suppl 1","key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1521-690X(09)70006-5","article-title":"5 Long-term acromegaly and associated cardiovascular complications: a case-based review.","volume":"23","author":"Colao","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R24-7-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.","volume":"100","author":"Lie","year":"1980","journal-title":"Am Heart J"},{"key":"R25-7-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart.","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/eje.0.1460303","article-title":"Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly.","volume":"146","author":"Colao","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2265.1998.00493.x","article-title":"Echocardiographic evidence for a direct effect of GHIGF-I hypersecretion on cardiac mass and function in young acromegalics.","volume":"49","author":"Minniti","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R28-7-20210203","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management.","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"R29-7-20210203","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1210\/jc.2004-1042","article-title":"The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study.","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-7-20210203","first-page":"666","article-title":"Cardiac hypertrophy and function in asymptomatic acromegaly.","volume":"12","author":"Morvan","year":"1991","journal-title":"Eur Heart J"},{"key":"R31-7-20210203","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/jc.2007-1189","article-title":"Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure.","volume":"92","author":"Fazio","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-7-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/14.1.26","article-title":"Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study.","volume":"14","author":"Fazio","year":"1993","journal-title":"Eur Heart J"},{"key":"R33-7-20210203","first-page":"193","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-7-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.2008.03292.x","article-title":"The GH-IGF-I axis and the cardiovascular system: clinical implications.","volume":"69","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R35-7-20210203","first-page":"441","article-title":"Impaired cardiac performance is a distinct feature of uncomplicated acromegaly.","volume":"79","author":"Fazio","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-7-20210203","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2265.2005.02370.x","article-title":"Hypertension in acromegaly and in the normal population: prevalence and determinants.","volume":"63","author":"Vitale","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R37-7-20210203","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1172\/JCI102977","article-title":"Body water and sodium in patients with acromegaly.","volume":"33","author":"Ikkos","year":"1954","journal-title":"J Clin Invest"},{"key":"R38-7-20210203","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jcem.87.4.8394","article-title":"GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis.","volume":"87","author":"Johannsson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-7-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2265.2000.00931.x","article-title":"Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor.","volume":"52","author":"Moller","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R40-7-20210203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF02336675","article-title":"Atrial natriuretic factor in patients with acromegaly.","volume":"38","author":"Deray","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"R41-7-20210203","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1046\/j.1365-2265.1998.00620.x","article-title":"Decreased regional blood flow in patients with acromegaly.","volume":"49","author":"Chanson","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R43-7-20210203","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2265.2000.01127.x","article-title":"Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction.","volume":"53","author":"Maison","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R44-7-20210203","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1210\/jcem.87.7.8643","article-title":"Early vascular alterations in acromegaly.","volume":"87","author":"Brevetti","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R45-7-20210203","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01256.x","article-title":"Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly.","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R46-7-20210203","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2265.2001.01281.x","article-title":"Characterization of premature atherosclerosis of carotid arteries in acromegalic patients.","volume":"54","author":"Otsuki","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R47-7-20210203","first-page":"1874","article-title":"Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R48-7-20210203","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/hrt.62.3.185","article-title":"Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle.","volume":"62","author":"Rodrigues","year":"1989","journal-title":"Br Heart J"},{"key":"R49-7-20210203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.eurheartj.a060047","article-title":"Arrhythmia profile in acromegaly.","volume":"13","author":"Kahaly","year":"1992","journal-title":"Eur Heart J"},{"key":"R50-7-20210203","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/jc.2002-021099","article-title":"High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study.","volume":"88","author":"Colao","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R51-7-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ghir.2006.02.002","article-title":"Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation.","volume":"16","author":"van der Klaauw","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"R52-7-20210203","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly.","volume":"86","author":"Bates","year":"1993","journal-title":"Q J Med"},{"key":"R54-7-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1530\/acta.0.1080026","article-title":"Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation.","volume":"108","author":"Baldwin","year":"1985","journal-title":"Acta Endocrinol"},{"key":"R55-7-20210203","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jcem.82.2.3648","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly.","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R56-7-20210203","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1001\/jama.1980.03310160041024","article-title":"Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome.","volume":"244","author":"Luboshitzky","year":"1980","journal-title":"JAMA"},{"key":"R57-7-20210203","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-7-20210203","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9149(94)90865-6","article-title":"Effects of octreotide on left ventricular mass in acromegaly.","volume":"74","author":"Tokgozoglu","year":"1994","journal-title":"Am J Cardiol"},{"key":"R59-7-20210203","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2265.1989.tb00266.x","article-title":"The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study.","volume":"30","author":"Thuesen","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R60-7-20210203","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/BF03344070","article-title":"Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.","volume":"25","author":"Lombardi","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"R61-7-20210203","first-page":"790","article-title":"Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.","volume":"77","author":"Merola","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R62-7-20210203","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7326\/0003-4819-113-12-921","article-title":"Cardiovascular effects of the somatostatin analog octreotide in acromegaly.","volume":"113","author":"Chanson","year":"1990","journal-title":"Ann Intern Med"},{"key":"R63-7-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/jcem.84.1.5368","article-title":"Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R64-7-20210203","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R65-7-20210203","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R66-7-20210203","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2265.2006.02639.x","article-title":"Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.","volume":"65","author":"Fatti","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R67-7-20210203","first-page":"258","article-title":"Effect of somatostatin on the conduction system of the heart.","volume":"38","author":"Bubinski","year":"1993","journal-title":"Kardiol Pol"},{"key":"R68-7-20210203","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4158\/EP.10.3.213","article-title":"AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly.","volume":"10","author":"Cook","year":"2004","journal-title":"Endocr Pract"},{"key":"R69-7-20210203","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance.","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R70-7-20210203","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"R72-7-20210203","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-148-10-200805200-00215","article-title":"Systematic review: the effects of growth hormone on athletic performance.","volume":"148","author":"Liu","year":"2008","journal-title":"Ann Intern Med"},{"key":"R73-7-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bjp.2008.99","article-title":"Growth hormone, IGF-I and insulin and their abuse in sport.","volume":"154","author":"Holt","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R74-7-20210203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ghir.2007.01.010","article-title":"Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users.","volume":"17","author":"Graham","year":"2007","journal-title":"Growth Horm IGF Res"},{"key":"R75-7-20210203","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1210\/jc.2004-0067","article-title":"The effects of time following acute growth hormone administration on metabolic and power output measures during acute exercise.","volume":"89","author":"Irving","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R76-7-20210203","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1210\/jc.2001-011797","article-title":"Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men.","volume":"87","author":"Lange","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R77-7-20210203","doi-asserted-by":"crossref","first-page":"E1326","DOI":"10.1152\/ajpendo.2001.281.6.E1326","article-title":"Effects of growth hormone on renal tubular handling of sodium in healthy humans.","volume":"281","author":"Hansen","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R78-7-20210203","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1210\/jc.2004-1209","article-title":"Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes.","volume":"90","author":"Berggren","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 3","key":"R79-7-20210203","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1113\/jphysiol.2005.089524","article-title":"No effect of growth hormone administration on substrate oxidation during exercise in young, lean men.","volume":"567","author":"Hansen","year":"2005","journal-title":"J Physiol (Lond)"},{"key":"R80-7-20210203","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11312100-000000000-00000","article-title":"Changes in endothelial dysfunction and associated cardiovascular disease morbidity markers in GH-IGF axis pathology.","volume":"9","author":"Graham","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"key":"R81-7-20210203","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.CIR.93.4.800","article-title":"Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation.","volume":"93","author":"Cittadini","year":"1996","journal-title":"Circulation"},{"key":"R82-7-20210203","first-page":"193","article-title":"Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study.","volume":"35","author":"Thuesen","year":"1988","journal-title":"Dan Med Bull"},{"key":"R84-7-20210203","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-2003-40702","article-title":"Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone.","volume":"24","author":"Karila","year":"2003","journal-title":"Int J Sports Med"},{"key":"R85-7-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0140-6736(90)91812-O","article-title":"Premature mortality due to cardiovascular disease in hypopituitarism.","volume":"336","author":"Rosen","year":"1990","journal-title":"Lancet"},{"key":"R86-7-20210203","first-page":"1169","article-title":"The effect of hypopituitarism on life expectancy.","volume":"81","author":"Bates","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R87-7-20210203","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.CIR.0000027563.44593.CC","article-title":"Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.","volume":"106","author":"Juul","year":"2002","journal-title":"Circulation"},{"key":"R88-7-20210203","doi-asserted-by":"crossref","first-page":"642","DOI":"10.7326\/0003-4819-139-8-200310210-00007","article-title":"Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study.","volume":"139","author":"Vasan","year":"2003","journal-title":"Ann Intern Med"},{"key":"R89-7-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/jc.2003-030967","article-title":"The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study.","volume":"89","author":"Laughlin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R90-7-20210203","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2265.2004.02105.x","article-title":"Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency.","volume":"61","author":"Colao","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"suppl A","key":"R91-7-20210203","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ghir.2006.03.006","article-title":"Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy.","volume":"16","author":"Colao","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"R92-7-20210203","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/jc.2007-2810","article-title":"Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency.","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R93-7-20210203","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1210\/jc.2005-2566","article-title":"The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis.","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R94-7-20210203","first-page":"492","article-title":"Energy and macronutrient intake in growth hormone-deficient adults: the effect of growth hormone replacement.","volume":"49","author":"Snel","year":"1995","journal-title":"Eur J Clin Nutr"},{"key":"R95-7-20210203","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/0026-0495(95)90004-7","article-title":"Growth hormone-deficient adults are insulin-resistant.","volume":"44","author":"Johansson","year":"1995","journal-title":"Metab Clin Exp"},{"key":"R96-7-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-133-2-200007180-00010","article-title":"Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial.","volume":"133","author":"Sesmilo","year":"2000","journal-title":"Ann Intern Med"},{"key":"R97-7-20210203","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1210\/jc.2005-2227","article-title":"Endocrine Societys Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.","volume":"91","author":"Molitch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R98-7-20210203","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/BF03349263","article-title":"Pituitary Society; European Neuroendocrine Association. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.","volume":"31","author":"Giustina","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"R99-7-20210203","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1210\/jc.2005-0185","article-title":"Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).","volume":"90","author":"Verhelst","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R101-7-20210203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ghir.2009.09.005","article-title":"Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.","volume":"20","author":"Bidlingmaier","year":"2010","journal-title":"Growth Horm IGF Res"},{"key":"R102-7-20210203","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1210\/jc.2004-2247","article-title":"Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency.","volume":"90","author":"Colao","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R103-7-20210203","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1210\/jc.2004-1844","article-title":"Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement.","volume":"90","author":"Colao","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R104-7-20210203","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0002-9149(02)02885-0","article-title":"Effect of congestive heart failure on the insulin-like growth factor-1 system.","volume":"90","author":"Anwar","year":"2002","journal-title":"Am J Cardiol"},{"key":"R105-7-20210203","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1006\/jmcc.2001.1441","article-title":"Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque.","volume":"33","author":"Okura","year":"2001","journal-title":"J Mol Cell Cardiol"},{"key":"R106-7-20210203","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/hh0901.090305","article-title":"Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling.","volume":"88","author":"Patel","year":"2001","journal-title":"Circ Res"},{"key":"R107-7-20210203","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/BF03347225","article-title":"Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.","volume":"28","author":"Colao","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"R108-7-20210203","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1210\/jc.2009-1295","article-title":"Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity.","volume":"94","author":"Makimura","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R109-7-20210203","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/0140-6736(92)92892-J","article-title":"Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.","volume":"340","author":"Markussis","year":"1992","journal-title":"Lancet"},{"key":"R110-7-20210203","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/jcem.82.5.3951","article-title":"Increased arterial intima-media thickness in childhood-onset growth hormone deficiency.","volume":"82","author":"Capaldo","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R111-7-20210203","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/01.CIR.103.4.520","article-title":"Abnormal vascular reactivity in growth hormone deficiency.","volume":"103","author":"Capaldo","year":"2001","journal-title":"Circulation"},{"key":"R112-7-20210203","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1210\/jc.2005-0091","article-title":"Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters.","volume":"90","author":"Lanes","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R113-7-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2265.1999.00671.x","article-title":"Endothelial dysfunction in hypopituitary adults with growth hormone deficiency.","volume":"50","author":"Evans","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R114-7-20210203","first-page":"1658","article-title":"Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency.","volume":"77","author":"Merola","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R115-7-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.1998.00281.x","article-title":"Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency.","volume":"48","author":"Longobardi","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R116-7-20210203","first-page":"1671","article-title":"Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses.","volume":"77","author":"Amato","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R117-7-20210203","first-page":"552","article-title":"Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood.","volume":"80","author":"Nass","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R118-7-20210203","first-page":"659","article-title":"Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.","volume":"80","author":"Valcavi","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R119-7-20210203","first-page":"1329","article-title":"Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency.","volume":"84","author":"Borson-Chazot","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R120-7-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1530\/EJE-08-0179","article-title":"Recombinant human GH replacement increases CD34 cells and improves endothelial function in adults with GH deficiency.","volume":"159","author":"van der Klaauw","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R121-7-20210203","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1210\/jc.2005-0208","article-title":"Transition Study Group. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial.","volume":"90","author":"Mauras","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R122-7-20210203","first-page":"21","article-title":"Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient adults. An 18-month randomised, placebo-controlled, double-blind study.","volume":"58","author":"Sneppen","year":"2002","journal-title":"Horm Res"},{"key":"R123-7-20210203","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2007-1636","article-title":"Congenital growth hormone (GH) deficiency and atherosclerosis: effects of GH replacement in GH-naive adults.","volume":"92","author":"Oliveira","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R124-7-20210203","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1210\/jc.2005-0597","article-title":"Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis Results of a two-year open, prospective study in young adult men and women with severe GH deficiency.","volume":"90","author":"Colao","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R125-7-20210203","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-07-0554","article-title":"Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.","volume":"158","author":"Joaquin","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R127-7-20210203","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1210\/jc.2003-030223","article-title":"Growth hormone increases vascular cell adhesion molecule 1 expression: in vivo and in vitro evidence.","volume":"89","author":"Hansen","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R128-7-20210203","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1463-1326.2004.00463.x","article-title":"Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects.","volume":"7","author":"Heliovaara","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"R129-7-20210203","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1210\/jc.2007-2371","article-title":"Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.","volume":"93","author":"Beauregard","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R130-7-20210203","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1210\/jc.2003-031474","article-title":"Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study.","volume":"89","author":"Christ","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R131-7-20210203","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1172\/JCI119398","article-title":"Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat.","volume":"99","author":"Rudling","year":"1997","journal-title":"J Clin Invest"},{"key":"R132-7-20210203","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1210\/jcem.84.4.5605","article-title":"The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R133-7-20210203","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1530\/eje.0.1410481","article-title":"Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group.","volume":"141","author":"Sanmarti","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"R134-7-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/eje.1.02179","article-title":"Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults -a KIMS database analysis.","volume":"155","author":"Abs","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"R135-7-20210203","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0026-0495(94)90245-3","article-title":"Serum lipid levels in growth hormone-deficient men.","volume":"43","author":"de Boer","year":"1994","journal-title":"Metab Clin Exp"},{"key":"R136-7-20210203","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ghir.2010.02.002","article-title":"The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.","volume":"20","author":"Deepak","year":"2010","journal-title":"Growth Horm IGF Res"},{"key":"R137-7-20210203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2265.1995.tb01860.x","article-title":"Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults.","volume":"42","author":"Beshyah","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R138-7-20210203","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/ajcn\/55.5.918","article-title":"Body composition in growth hormone-deficient adults.","volume":"55","author":"Binnerts","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"R139-7-20210203","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM198912283212605","article-title":"The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.","volume":"321","author":"Salomon","year":"1989","journal-title":"N Engl J Med"},{"key":"R140-7-20210203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/acta.0.1290195","article-title":"Cardiovascular risk factors in adult patients with growth hormone deficiency.","volume":"129","author":"Rosen","year":"1993","journal-title":"Acta Endocrinol"},{"key":"R141-7-20210203","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1210\/jc.2002-021943","article-title":"Short- and long-term effects of growth hormone (GH) replacement on protein metabolism in GH-deficient adults.","volume":"88","author":"Shi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R142-7-20210203","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1161\/01.CIR.0000100720.01867.1D","article-title":"Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis.","volume":"108","author":"Maison","year":"2003","journal-title":"Circulation"},{"key":"R143-7-20210203","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1210\/jc.2002-020542","article-title":"Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.","volume":"88","author":"Bramnert","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R144-7-20210203","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1210\/jc.2004-1239","article-title":"Adiponectin, leptin, and erythrocyte sodiumlithium countertransport activity, but not resistin, are related to glucose metabolism in growth hormone-deficient adults.","volume":"90","author":"Svensson","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R145-7-20210203","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/BF03345771","article-title":"Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults.","volume":"32","author":"Valle","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"R146-7-20210203","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2265.2005.02359.x","article-title":"Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.","volume":"63","author":"Yuen","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R147-7-20210203","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03346297","article-title":"Association of insulin resistance and nocturnal fall of blood pressure in GH-deficient adults during GH replacement.","volume":"30","author":"Brasil","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"R148-7-20210203","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ghir.2008.01.002","article-title":"Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.","volume":"18","author":"Fideleff","year":"2008","journal-title":"Growth Horm IGF Res"},{"key":"R149-7-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2265.1999.00682.x","article-title":"Cardiovascular disease and risk factors in adults with hypopituitarism.","volume":"50","author":"Beshyah","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R150-7-20210203","first-page":"1881","article-title":"Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency.","volume":"83","author":"Sverrisdottir","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R151-7-20210203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00126097-200204000-00001","article-title":"Ambulatory monitoring of blood pressure in growth hormone-deficient adults.","volume":"7","author":"Conceicao","year":"2002","journal-title":"Blood Press Monit"},{"key":"R152-7-20210203","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1365-2265.2002.01491.x","article-title":"Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency.","volume":"56","author":"Ahmad","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R153-7-20210203","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/oxfordjournals.eurheartj.a015237","article-title":"Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans.","volume":"18","author":"Fazio","year":"1997","journal-title":"Eur Heart J"},{"key":"R154-7-20210203","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199603283341301","article-title":"A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.","volume":"334","author":"Fazio","year":"1996","journal-title":"N Engl J Med"},{"key":"R155-7-20210203","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/157340309788970306","article-title":"The GHIGF-1 Axis and Heart Failure.","volume":"5","author":"Castellano","year":"2009","journal-title":"Curr Cardiol Rev"},{"key":"R156-7-20210203","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1161\/01.CIR.100.19.2003","article-title":"Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure.","volume":"100","author":"Houck","year":"1999","journal-title":"Circulation"},{"key":"R157-7-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0167-5273(92)90061-7","article-title":"Preservation of the myocardial collagen framework by human growth hormone in experimental infarctions and reduction in the incidence of ventricular aneurysms.","volume":"35","author":"Castagnino","year":"1992","journal-title":"Int J Cardiol"},{"key":"R158-7-20210203","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/01.CIR.92.2.262","article-title":"Growth hormone improves cardiac performance in experimental heart failure.","volume":"92","author":"Yang","year":"1995","journal-title":"Circulation"},{"key":"R159-7-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0008-6363(98)00181-3","article-title":"Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction.","volume":"40","author":"Grimm","year":"1998","journal-title":"Cardiovasc Res"},{"key":"R160-7-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0008-6363(99)00058-9","article-title":"Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes.","volume":"43","author":"Kinugawa","year":"1999","journal-title":"Cardiovasc Res"},{"key":"R161-7-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.RES.0000051885.70159.12","article-title":"Insulin-like growth factor-1 exerts Ca2-dependent positive inotropic effects in failing human myocardium.","volume":"92","author":"von Lewinski","year":"2003","journal-title":"Circ Res"},{"key":"R162-7-20210203","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1161\/01.RES.86.11.1107","article-title":"Apoptosis and heart failure: A critical review of the literature.","volume":"86","author":"Kang","year":"2000","journal-title":"Circ Res"},{"key":"R163-7-20210203","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.142.7.8242","article-title":"The proliferative and antiapoptotic actions of growth hormone and insulin-like growth factor-1 are mediated through distinct signaling pathways in the Pro-B BaF3 cell line.","volume":"142","author":"Baixeras","year":"2001","journal-title":"Endocrinology"},{"key":"R164-7-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1210\/endo.142.1.7892","article-title":"Growth hormone exerts antiapoptotic and proliferative effects through two different pathways involving nuclear factor-kappaB and phosphatidylinositol 3-kinase.","volume":"142","author":"Jeay","year":"2001","journal-title":"Endocrinology"},{"key":"R165-7-20210203","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1210\/jc.2006-1313","article-title":"Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis.","volume":"92","author":"Le Corvoisier","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R166-7-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/01.CIR.99.1.18","article-title":"Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity.","volume":"99","author":"Genth-Zotz","year":"1999","journal-title":"Circulation"},{"key":"R167-7-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1540-8191.2001.tb00497.x","article-title":"Growth hormone treatment in dilated cardiomyopathy.","volume":"16","author":"Perrot","year":"2001","journal-title":"J Card Surg"},{"key":"R168-7-20210203","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(97)11329-0","article-title":"Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.","volume":"351","author":"Osterziel","year":"1998","journal-title":"Lancet"},{"key":"R169-7-20210203","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2362.1997.1430692.x","article-title":"Growth hormone improves cardiac function in rats with experimental myocardial infarction.","volume":"27","author":"Isgaard","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"R170-7-20210203","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0195-668X(02)00740-6","article-title":"A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies.","volume":"24","author":"Cittadini","year":"2003","journal-title":"Eur Heart J"},{"key":"R171-7-20210203","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/S0195-668X(03)00480-9","article-title":"Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy.","volume":"24","author":"Adamopoulos","year":"2003","journal-title":"Eur Heart J"},{"key":"R172-7-20210203","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mhj.2002.124052","article-title":"Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fassoluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.","volume":"144","author":"Adamopoulos","year":"2002","journal-title":"Am Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0b013e318248a3e1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:35:31Z","timestamp":1786048531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201207000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":162,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e318248a3e1","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}